STOCK TITAN

[8-K] BiomX Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

BiomX Inc. furnished an 8-K reporting that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The filing does not include the underlying financial statements or numeric results; instead, the press release itself is furnished as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.

The submission is a disclosure furnishing rather than a full presentation of results within the 8-K text. The report is signed on behalf of the company by Chief Executive Officer Jonathan Solomon.

BiomX Inc. ha presentato un rapporto 8-K nel quale comunica di aver rilasciato un comunicato stampa che annuncia i risultati finanziari per il trimestre chiuso al 30 giugno 2025. La documentazione non include i bilanci sottostanti né i risultati numerici; il comunicato stampa è invece fornito come Exhibit 99.1 e una pagina di copertura Inline XBRL è inclusa come Exhibit 104.

Si tratta di una mera fornitura informativa (disclosure furnishing) e non di una presentazione completa dei risultati nel testo dell'8-K. Il rapporto è firmato per conto della società dall'Amministratore Delegato Jonathan Solomon.

BiomX Inc. presentó un 8-K informando que emitió un comunicado de prensa que anuncia sus resultados financieros para el trimestre concluido el 30 de junio de 2025. La presentación no incluye los estados financieros subyacentes ni los resultados numéricos; en su lugar, el comunicado de prensa se adjunta como Exhibit 99.1 y se incluye una portada Inline XBRL como Exhibit 104.

La remisión constituye una puesta a disposición informativa (disclosure furnishing) y no una exposición completa de resultados en el texto del 8-K. El informe está firmado en nombre de la empresa por el Director Ejecutivo Jonathan Solomon.

BiomX Inc.는 2025년 6월 30일로 종료된 분기의 재무 결과를 발표하는 보도자료를 발행했다고 보고하는 8-K를 제출했습니다. 해당 제출서류에는 기초 재무제표나 수치상의 결과가 포함되어 있지 않으며, 대신 보도자료 자체가 Exhibit 99.1로 제공되고 Inline XBRL 표지가 Exhibit 104로 첨부되어 있습니다.

이 제출은 8-K 본문에서 결과를 완전하게 제시한 것이 아니라 공시용 제공(disclosure furnishing)에 해당합니다. 보고서는 회사 대표로서 최고경영자 Jonathan Solomon의 서명으로 제출되었습니다.

BiomX Inc. a déposé un formulaire 8-K indiquant qu'elle a publié un communiqué annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025. Le dépôt n'inclut pas les états financiers sous-jacents ni les résultats chiffrés ; le communiqué est en revanche fourni comme Exhibit 99.1 et une page de couverture Inline XBRL est jointe comme Exhibit 104.

Il s'agit d'une mise à disposition d'information (disclosure furnishing) et non d'une présentation complète des résultats dans le texte du 8-K. Le rapport est signé au nom de la société par le Directeur Général Jonathan Solomon.

BiomX Inc. hat ein Formblatt 8-K eingereicht, in dem mitgeteilt wird, dass ein Pressemitteilung veröffentlicht wurde, die die Finanzergebnisse für das Quartal zum 30. Juni 2025 ankündigt. Die Einreichung enthält nicht die zugrunde liegenden Abschlüsse oder zahlenmäßigen Ergebnisse; stattdessen ist die Pressemitteilung als Exhibit 99.1 beigefügt und eine Inline-XBRL-Titelseite als Exhibit 104 enthalten.

Es handelt sich um eine bloße Offenlegung (disclosure furnishing) und nicht um eine vollständige Darstellung der Ergebnisse im Text des 8-K. Der Bericht ist im Namen des Unternehmens vom Chief Executive Officer Jonathan Solomon unterzeichnet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine furnishing of a press release with Q2 2025 results; filing contains no financial data to evaluate impact.

The 8-K notifies investors that the company has publicly released its second quarter results and has attached that press release as Exhibit 99.1. Because the filing text itself does not include revenue, profit, cash flow, or other metrics, there is insufficient information here to assess earnings performance, trends, or valuation impact. Investors must review the referenced press release and any filed financial statements for material details.

TL;DR: Procedural disclosure shows governance compliance in furnishing required press release exhibits; no governance issues disclosed.

The report follows standard disclosure practice by furnishing the press release as an exhibit and embedding Inline XBRL cover data. The filing identifies the signing officer as CEO Jonathan Solomon. The document does not present any executive changes, board actions, or governance-related transactions, so there is no material governance information to evaluate within this filing.

BiomX Inc. ha presentato un rapporto 8-K nel quale comunica di aver rilasciato un comunicato stampa che annuncia i risultati finanziari per il trimestre chiuso al 30 giugno 2025. La documentazione non include i bilanci sottostanti né i risultati numerici; il comunicato stampa è invece fornito come Exhibit 99.1 e una pagina di copertura Inline XBRL è inclusa come Exhibit 104.

Si tratta di una mera fornitura informativa (disclosure furnishing) e non di una presentazione completa dei risultati nel testo dell'8-K. Il rapporto è firmato per conto della società dall'Amministratore Delegato Jonathan Solomon.

BiomX Inc. presentó un 8-K informando que emitió un comunicado de prensa que anuncia sus resultados financieros para el trimestre concluido el 30 de junio de 2025. La presentación no incluye los estados financieros subyacentes ni los resultados numéricos; en su lugar, el comunicado de prensa se adjunta como Exhibit 99.1 y se incluye una portada Inline XBRL como Exhibit 104.

La remisión constituye una puesta a disposición informativa (disclosure furnishing) y no una exposición completa de resultados en el texto del 8-K. El informe está firmado en nombre de la empresa por el Director Ejecutivo Jonathan Solomon.

BiomX Inc.는 2025년 6월 30일로 종료된 분기의 재무 결과를 발표하는 보도자료를 발행했다고 보고하는 8-K를 제출했습니다. 해당 제출서류에는 기초 재무제표나 수치상의 결과가 포함되어 있지 않으며, 대신 보도자료 자체가 Exhibit 99.1로 제공되고 Inline XBRL 표지가 Exhibit 104로 첨부되어 있습니다.

이 제출은 8-K 본문에서 결과를 완전하게 제시한 것이 아니라 공시용 제공(disclosure furnishing)에 해당합니다. 보고서는 회사 대표로서 최고경영자 Jonathan Solomon의 서명으로 제출되었습니다.

BiomX Inc. a déposé un formulaire 8-K indiquant qu'elle a publié un communiqué annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025. Le dépôt n'inclut pas les états financiers sous-jacents ni les résultats chiffrés ; le communiqué est en revanche fourni comme Exhibit 99.1 et une page de couverture Inline XBRL est jointe comme Exhibit 104.

Il s'agit d'une mise à disposition d'information (disclosure furnishing) et non d'une présentation complète des résultats dans le texte du 8-K. Le rapport est signé au nom de la société par le Directeur Général Jonathan Solomon.

BiomX Inc. hat ein Formblatt 8-K eingereicht, in dem mitgeteilt wird, dass ein Pressemitteilung veröffentlicht wurde, die die Finanzergebnisse für das Quartal zum 30. Juni 2025 ankündigt. Die Einreichung enthält nicht die zugrunde liegenden Abschlüsse oder zahlenmäßigen Ergebnisse; stattdessen ist die Pressemitteilung als Exhibit 99.1 beigefügt und eine Inline-XBRL-Titelseite als Exhibit 104 enthalten.

Es handelt sich um eine bloße Offenlegung (disclosure furnishing) und nicht um eine vollständige Darstellung der Ergebnisse im Text des 8-K. Der Bericht ist im Namen des Unternehmens vom Chief Executive Officer Jonathan Solomon unterzeichnet.

false 0001739174 0001739174 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 13, 2025

 

BiomX Inc.
(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-38762   82-3364020
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

22 Einstein St., Floor 4
Ness Ziona, Israel

  7414003
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +972 723942377

 

n/a
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   PHGE   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 13, 2025, BiomX Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release issued in connection with the announcement is furnished pursuant to this Item 2.02 as Exhibit 99.1 hereto.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit   Description
99.1   Press Release dated August 13, 2025 (furnished herewith)
104   Cover Page Interactive Data File (embedded within the Inline XBRL documents)

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOMX INC.
     
August 13, 2025 By: /s/ Jonathan Solomon
    Name:  Jonathan Solomon
    Title: Chief Executive Officer

 

2

 

FAQ

What did BiomX (PHGE) disclose in this 8-K?

The company disclosed that it issued a press release announcing its financial results for the quarter ended June 30, 2025, and furnished that press release as Exhibit 99.1.

Does the 8-K include financial statements or numeric results for Q2 2025?

No. The 8-K text does not include numeric financial results or financial statements; the press release itself is furnished as an exhibit.

Which exhibits are attached to the filing?

The filing lists Exhibit 99.1 (Press Release dated August 13, 2025) and Exhibit 104 (Cover Page Interactive Data File embedded in Inline XBRL).

Who signed the 8-K for BiomX?

The report is signed on behalf of BiomX by Jonathan Solomon, Chief Executive Officer.

What class of securities is listed for BiomX and where is it traded?

The filing shows Common Stock, $0.0001 par value trading under the symbol PHGE on the NYSE American exchange.
Biomx Inc

NYSE:PHGE

PHGE Rankings

PHGE Latest News

PHGE Latest SEC Filings

PHGE Stock Data

14.71M
19.97M
19.08%
47.7%
7.71%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Israel
NESS ZIONA